BTIG Research Boosts Natera (NASDAQ:NTRA) Price Target to $210.00

Natera (NASDAQ:NTRA) had its price objective hoisted by research analysts at BTIG Research from $200.00 to $210.00 in a research report issued on Thursday, Marketbeat reports. The firm currently has a “buy” rating on the medical research company’s stock. BTIG Research’s price objective would suggest a potential upside of 9.09% from the stock’s current price.

A number of other analysts also recently weighed in on NTRA. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Barclays reissued an “overweight” rating and issued a $210.00 target price (up from $190.00) on shares of Natera in a report on Friday, August 8th. Wells Fargo & Company initiated coverage on Natera in a report on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and set a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.59.

Natera Stock Down 1.3%

NTRA stock opened at $192.51 on Thursday. The company has a market cap of $26.42 billion, a PE ratio of -100.79 and a beta of 1.74. The business has a 50-day simple moving average of $171.29 and a 200 day simple moving average of $160.18. Natera has a 52 week low of $117.27 and a 52 week high of $198.99.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the previous year, the company earned ($0.30) earnings per share. The business’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, analysts anticipate that Natera will post -1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 14,083 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00. Following the transaction, the chief executive officer directly owned 154,072 shares in the company, valued at approximately $24,651,520. This represents a 8.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rowan E. Chapman sold 2,750 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,446 shares of company stock valued at $11,207,899. Insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. HighPoint Advisor Group LLC increased its position in Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock worth $308,000 after purchasing an additional 468 shares during the period. Park Avenue Securities LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $1,525,000. Amalgamated Bank grew its stake in Natera by 9.8% in the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after acquiring an additional 740 shares during the period. Comerica Bank grew its stake in Natera by 24.1% in the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock worth $19,954,000 after acquiring an additional 27,379 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock valued at $120,000 after buying an additional 207 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.